Clinical and economic outcomes of pharmacist-managed antiepileptic drug therapy

Pharmacotherapy

Volumn 26, Issue 10, 2006, Pages 1369-1378

  Bond, C A ^a   Raehl, Cynthia L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiepileptic drug therapy; Clinical pharmacy services; Collaborative drug therapy; Complications; Costs; Death rate; Epilepsy; Hospital length of stay; LOS; Seizure disorders

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; ASPIRATION PNEUMONIA; DATA BASE; ECONOMIC ASPECT; EPILEPSY; HEALTH CARE QUALITY; HOSPITAL CHARGE; HOSPITAL PATIENT; HUMAN; LABORATORY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICARE; MORTALITY; PHARMACIST; RASH; SEIZURE; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; COOPERATIVE BEHAVIOR; DATA COLLECTION; EPILEPSY; HUMANS; LENGTH OF STAY; MEDICARE; PATIENT CARE TEAM; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; TREATMENT OUTCOME; UNITED STATES;

EID: 33749493824     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.10.1369     Document Type: Article

References (56)

1. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: monitoring and patient education-2003. Am J Health-Syst Pharm 2004;61:457-71.
2. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006;26(5):601-8.
3. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635-45.
4. Institute of Medicine. Enhancing federal health care quality programs. Washington, DC: National Academy Press, 2003:1.
5. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academy Press, 2001:1.
6. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Expanded modified Medicare provider analysis and review (MedPAR-Hospital [National] FY 1998) on IBM 3480 tape cartridges. Baltimore, MD: Department of Health and Human Services, 1999.
7. Bond CA, Raehl CL, Pitterle ME, Franke T. Health care professional staffing, hospital characteristics, and hospital mortality rates. Pharmacotherapy 1999;19(2):130-8.
8. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and hospital mortality rates. Pharmacotherapy 1999;19(5):556-64.
9. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacist staffing, and drug costs in United States hospitals. Pharmacotherapy 1999;19(12)1354-62.
10. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacy staffing, and the total cost of care in United States hospitals. Pharmacotherapy 2000;20(6);609-21.
11. Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy 2001;21(2):129-41.
12. Bond CA, Raehl CI, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy 2002;22(2):134-47.
13. Bond CA, Raehl CL, Franke T. Medication errors in United States hospitals. Pharmacotherapy 2001;21(9):1023-36.
14. Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy 2003;23(1):113-32.
15. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-70.
16. Schumock GT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services: 1988-1995. Pharmacotherapy 1996;16(6):1188-208.
17. Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control: a four year ambulatory care model. Arch Intern Med 1984;144:1159-62.
18. Monson RA, Bond CA, Schuna A. Role of the clinical pharmacist in improving outpatient drug therapy. Arch Intern Med 1981;141:1441-4.
19. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure team. Arch Intern Med 1999;159:1939-45.
20. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-20.
21. Clapham CE, Hepler CE, Reinders TP, et al. Economic consequences of two drug-use control systems in a teaching hospital. Am J Hosp Pharm 1988;45:2329-40.
22. Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. Pharmacotherapy 1996;16(4):708-14.
23. McKenney JM, Wasserman AH. Effect of advanced pharmaceutical services on the incidence of adverse drug reactions. Am J Hosp Pharm 1979;36:1691-7.
24. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and Transfusions. Pharmacotherapy 2004;24(8)953-63.
25. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-provided aminoglycoside or vancomycin management in hospitalized Medicare patients. Am J Health-Syst Pharm 2005;62:1596-605.
26. Fowler JB, Ryan M, Kasarskis EJ. Phenytoin monitoring of patients in a long-term care facility. Hosp Pharm 1998;33:1097-101.
27. Brophy GM, Tesoro EP, Schrote GL, Garnett WR. Pharmacist impact on posttraumatic seizure prophylaxis in patients with head injury. Pharmacotherapy 2002;22(2):251-5.
28. Elenbaas RM, Payne VW, Bauman JL. Influence of clinical pharmacist consultations on the use of drug blood level tests. Am J Hosp Pharm 1980;37:61-4.
29. Maddox RR, Vanderveen TW, Jones EM, et al. Collaborative clinical pharmacokinetics services. Am J Hosp Pharm 1981;38:524-9.
30. Levin B, Cohen SS, Birmingham PH. Effect of pharmacist intervention on the use of serum drug assays. Am J Hosp Pharm 1981;38:845-51.
31. Tush GM, Garnett WR. Pharmacist impact on phenytoin concentration monitoring in the neuroscience intensive care unit [abstr]. Pharmacotherapy 1998;18(5):1169.
32. Garnett WR, Goldberg JA, Lowenthal W. Implementation and evaluation of clinical pharmacy services in an extended care facility. Gerontologist 1981;21(2):151-7.
33. Hatoum HT, Catizone C, Hutchinson RA, Purohit A. An eleven-year review of the pharmacy literature: documentation of the value and acceptance of clinical pharmacy. Drug Intell Clin Pharm 1986;20:33-48.
34. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals. Pharmacotherapy 2006;26(6):735-47.
35. Raehl CL, Bond CA. 1998 national clinical pharmacy services study. Pharmacotherapy 2000;20(4):436-60.
36. Raehl CL, Bond CA, Pitterle ME. 1995 national clinical pharmacy services survey. Pharmacotherapy 1998;18(2):302-26.
37. Raehl CL, Bond CA, Pitterle ME. Hospital pharmacy services in the Great Lakes region. Am J Hosp Pharm 1990;49:1283-303.
38. Raehl CL, Bond CA, Pitterle ME. Pharmaceutical services in U.S. hospitals in 1989. Am J Hosp Pharm 1992;49:323-46.
39. Bond CA, Raehl CL, Pitterle ME. 1992 national clinical pharmacy services study. Pharmacotherapy 1994;14(3);282-304.
40. American Hospital Association. Abridged guide to the healthcare field on diskettes 1998. Chicago, IL: American Hospital Association, 1999.
41. Unicor Medical, Inc. ICD-9CM easy coder. Montgomery, AL: Unicor Medical, Inc., 1998.
42. Rosko MD, Broyles RW. The economics of health care: a reference handbook. Westport, CT: Greenwood Press, 1998.
43. Prospective Payment Assessment Commission. Medicare prospective payment and the American health care system. HCFA publication no. HE 22.21/3:398. Washington, DC: Health Care Financing Administration, 1990.
44. Hammond RW, Schwartz AH, Campbell MJ, et al. Collaborative drug therapy management by pharmacists-2003. Pharmacotherapy 2003;23(9):1210-25.
45. Dubois RW, Brooks RH, Rodgers WH. Adjusted hospital death rates: a potential screen quality of medical care. Am J Public Health 1987;77:1162-7.
46. Krakauer H, Bailey RC, Skellan KJ, Stewart JD, Hartz AJ. Evaluation of the HCFA model for the analysis of mortality following hospitalization. Health Serv Res 1992;27(3):317-35.
47. Hartz AJ, Krakauer H, Kuhn EM, et al. Hospital characteristics and mortality rates. N Engl J Med 1989;321:1720-5.
48. Keeler EB, Rubenstein LV, Kahn KL, et al. Hospital characteristics and quality of care. JAMA 1992;268:1709-14.
49. Bond CA, Raehl CL, Pitterle ME. Staffing and the cost of clinical and hospital pharmacy services in United States hospitals. Pharmacotherapy 1999;19(6):767-81.
50. Kelly WN. Potential risks and prevention, part 1: fatal adverse drug events. Am J Health-Syst Pharm 2001;58:1317-24.
51. Kelley WN. Potential risks and prevention, part 2: drug-induced permanent disabilities. Am J Health-Syst Pharm 2001;58:1325-9.
52. Kelly WN. Potential risks and prevention, part 4: reports of significant adverse drug events. Am J Health-Syst Pharm 2001;58:1406-12.
53. Pfeffer J, Sutton RI. Evidenced-based management [online exclusive article]. Harvard Business Review, January 2006. Available from http://www.hbsp.org. Accessed February 20, 2006.
54. Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy 2004;24(4):427-40.
55. Hazzard WR, Blass JP, Ettinger WH, Ouslander JG. Principles of geriatric medicine and gerontology, 5th ed. New York: McGraw-Hill, 2003:940-9, 1549-51.
56. Lezzoni LI. Assessing quality using administrative data. Ann Intern Med 1997;127(8 pt 2):666-74.